Literature DB >> 11720792

Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: implications for axon-glia signaling.

A K Urazaev1, J G Buttram, J P Deen, B S Gafurov, B S Slusher, R M Grossfeld, E M Lieberman.   

Abstract

Crayfish nerve fibers incubated with radiolabeled glutamate or glutamine accumulate these substrates and synthesize radioactive N-acetylaspartylglutamate (NAAG). Upon stimulation of the medial giant nerve fiber, NAAG is the primary radioactive metabolite released. Since NAAG activates a glial hyperpolarization comparable to that initiated by glutamate or axonal stimulation through the same receptor, we have proposed that it is the likely mediator of interactions between the medial giant axon and its periaxonal glia. This manuscript reports investigations of possible mechanisms for termination of NAAG-signaling activity. N-acetylaspartyl-[(3)H]glutamate was not accumulated from the bath saline by unstimulated crayfish giant axons or their associated glia during a 30-min incubation. Stimulation of the central nerve cord at 50 Hz during the last minute of the incubation dramatically increased the levels of radiolabeled glutamate, NAAG, and glutamine in the medial giant axon and its associated glia. These results indicate that stimulation-sensitive peptide hydrolysis and metabolic recycling of the radiolabeled glutamate occurred. There was a beta-NAAG-, quisqualate- and 2-(phosphonomethyl)-pentanedioic acid-inhibitable glutamate carboxypeptidase II activity in the membrane fraction of central nerve fibers, but not in axonal or glial cytoplasmic fractions. Inactivation of this enzyme by 2-(phosphonomethyl)-pentanedioic acid or inhibition of N-methyl-D-aspartate (NMDA) receptors by MK801 reduced the glial hyperpolarization activated by high-frequency stimulation. These results indicate that axon-to-glia signaling is terminated by NAAG hydrolysis and that the glutamate formed contributes to the glial electrical response in part via activation of NMDA receptors. Both NAAG release and an increase in glutamate carboxypeptidase II activity appear to be induced by nerve stimulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720792     DOI: 10.1016/s0306-4522(01)00393-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.

Authors:  Morris H Baslow; Victor V Dyakin; Karen L Nowak; Basalingappa L Hungund; David N Guilfoyle
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

3.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.

Authors:  Ghanashyam D Ghadge; Barbara S Slusher; Amos Bodner; Mauro Dal Canto; Krystyna Wozniak; Ajit G Thomas; Camilo Rojas; Takashi Tsukamoto; Pavel Majer; Richard J Miller; Anna Liza Monti; Raymond P Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

4.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

5.  Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats.

Authors:  Michelle C Potter; Krystyna M Wozniak; Noelle Callizot; Barbara S Slusher
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.